'Primovax' - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Trial Profile

'Primovax' - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2014

At a glance

  • Drugs Tertomotide (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PrimoVax
  • Sponsors Pharmexa
  • Most Recent Events

    • 31 May 2009 Results presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO 2009)
    • 13 May 2008 Status changed from recruiting to discontinued based on information from a Pharmexa media release.
    • 13 May 2008 Enrolment was terminated after a preliminary analysis of data from 174 patients showed no additional survival benefits of combination therapy compared with monotherapy. Final conclusions will be based on full data analyses and further follow-up.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top